Charles River Laboratories International (CRL) to Release Quarterly Earnings on Wednesday

Charles River Laboratories International (NYSE:CRLGet Free Report) will announce its earnings results before the market opens on Wednesday, February 14th. Analysts expect the company to announce earnings of $2.39 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Charles River Laboratories International Price Performance

NYSE CRL opened at $225.78 on Tuesday. The company has a market cap of $11.58 billion, a PE ratio of 24.44, a price-to-earnings-growth ratio of 2.29 and a beta of 1.38. The company has a quick ratio of 1.16, a current ratio of 1.45 and a debt-to-equity ratio of 0.76. The firm’s 50-day simple moving average is $220.42 and its two-hundred day simple moving average is $204.14. Charles River Laboratories International has a 52 week low of $161.65 and a 52 week high of $257.17.

Insider Activity

In other news, COO Birgit Girshick acquired 1,322 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were acquired at an average cost of $187.82 per share, with a total value of $248,298.04. Following the acquisition, the chief operating officer now directly owns 44,449 shares of the company’s stock, valued at $8,348,411.18. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC lifted its stake in shares of Charles River Laboratories International by 15.4% during the 1st quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock worth $378,000 after acquiring an additional 178 shares during the last quarter. Panagora Asset Management Inc. lifted its position in shares of Charles River Laboratories International by 236.5% during the first quarter. Panagora Asset Management Inc. now owns 2,722 shares of the medical research company’s stock worth $773,000 after purchasing an additional 1,913 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Charles River Laboratories International by 6.6% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock valued at $1,917,000 after purchasing an additional 418 shares during the period. Great West Life Assurance Co. Can grew its holdings in shares of Charles River Laboratories International by 0.4% in the first quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock worth $7,465,000 after purchasing an additional 107 shares during the last quarter. Finally, Raymond James Trust N.A. increased its stake in Charles River Laboratories International by 33.7% in the 1st quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock worth $433,000 after buying an additional 384 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CRL. Citigroup raised their price target on shares of Charles River Laboratories International from $190.00 to $215.00 and gave the company a “neutral” rating in a report on Monday, December 11th. JPMorgan Chase & Co. boosted their target price on Charles River Laboratories International from $210.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. UBS Group lowered their price target on Charles River Laboratories International from $250.00 to $215.00 and set a “buy” rating on the stock in a report on Thursday, November 9th. Finally, Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $205.00 and set an “equal weight” rating for the company in a report on Friday, November 10th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $233.31.

Check Out Our Latest Analysis on CRL

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

See Also

Earnings History for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.